Breaking News

SunTrust analyst Sandy Draper raised the firm's price target on Teladoc to $200 from $144, saying that while he was not surprised by the company's upside in utilization trends reported in Q1, he did not expect the higher speed of raised expectations for paid membership growth. While Draper believes that utilization trends for Teladoc will settle at a "higher new normal", the stock valuation keeps his rating at Hold.

Deutsche Bank analyst George Hill raised the firm's price target on Teladoc to $184 from $172 and keeps a Buy rating on the shares following the company's Q1 results.

BofA analyst Allen Lutz notes that Twilio (TWLO) announced it was selected by Epic Systems to power its new telehealth service. The app allows physicians to provide video visits with patients, review medical history, and update clinical documentation. The analyst notes that Twilio's press release highlights the level of urgency that many healthcare stakeholders are feeling to provide clients with access to telemedicine. In his view, Epic's industry leading position in the academic medical center market creates an opportunity to cross-sell, which could limit Teladoc's (TDOC) reach in this vertical. Lutz does not believe that Teladoc has a significant exposure to the hospital/health system market at this time, but does think that investors view this as an attractive growth market for the company. Furthermore, he expects other healthcare stakeholders such as payers are similarly focused on accelerating longer term strategies related to telemedicine which are likely to create incremental opportunities and threats for Teladoc. The analyst has a Neutral rating and a $194 price target on Teladoc's shares.

RBC Capital analyst Sean Dodge raised the firm's price target on Teladoc to $200 from $150 and keeps an Outperform rating on the shares. The analyst notes that the COVID-19 outbreak has accelerated the demand for telehealth, and while the company's Q1 results were largely in-line with its pre-announcement, the company's updated outlook increased the midpoints of its revenue and EBITDA FY20 ranges to "impressive" 16% and 15% growth rates respectively.

SVB Leerink analyst Stephanie Davis Demko raised the firm's price target on Teladoc to $197 from $180 and keeps an Outperform rating on the shares. Despite weakness in the shares, the analyst believes momentum favors Teledoc following a significant guidance raise that could still prove conservative. With Teladoc positioned as a "sleep easy" name in highly uncertain times, Davis Demko expects the company to sustain its premium trading multiple throughout the year.

JPMorgan analyst Lisa Gill raised the firm's price target on Teladoc to $194 from $182 and reiterates an Overweight rating on the shares. The company reported "strong" Q1 results amid an accelerating rate of telehealth adoption, Gill tells investors in a research note.

Credit Suisse analyst Jailendra Singh raised the firm's price target on Teladoc to $165 from $152 and keeps a Neutral rating on the shares. The analyst notes that the company's Q1 results on both revenues and EBITDA tracked preannouncement. Further, he points out that Teledoc raised its 2020 revenue outlook to $800M-$825M.